title: Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia.
abstract: OBJECTIVE
  We aimed to evaluate the role of fat and cholecystokinin (CCK) in the pathophysiology of functional dyspepsia (FD) by investigating symptoms and plasma CCK levels following increasing doses of duodenal lipid during gastric distension, and the effect of CCK-A receptor blockade.
  
  
  METHODS
  In study A, six FD patients were studied on three occasions during duodenal infusion of saline or lipid (1.1 (L-1) or 2 kcal/min (L-2)) and proximal gastric distensions. Six healthy subjects were also studied as controls during L-2 only. In study B, the effect of the CCK-A antagonist dexloxiglumide (5 mg/kg/h) on L-2 induced symptoms was studied in 12 FD patients. Changes in gastric volume at minimal distending pressure and plasma CCK (study A) were assessed, gastric distensions were performed using a barostat, and dyspeptic symptoms were monitored.
  
  
  RESULTS
  Lipid increased gastric volume compared with saline (DeltaV (ml): saline 15 (20), L-1 122 (42), L-2 114 (28)) in patients and even more so in controls (221 (37); p<0.05). During distensions, symptoms were greater during L-2 than during saline or L-1, and greater in patients than in controls, while gastric compliance was smaller in patients than in controls (p<0.05). Lipid increased plasma CCK levels in patients and controls (p>0.05). Dexloxiglumide abolished the increase in gastric volume (DeltaV (ml): dexloxiglumide 17 (9), placebo 186 (49)) and dyspeptic symptoms (sum of scores: dexloxiglumide 24 (7), placebo 44 (19)) during duodenal lipid infusion. Dexloxiglumide also reduced gastric compliance (ml/mm Hg: dexloxiglumide 51 (7), placebo 72 (11)) and symptoms (sum of scores: dexloxiglumide 101 (17), placebo 154 (21)) during gastric distension.
  
  
  CONCLUSIONS
  CCK-A receptors are involved in the generation of dyspeptic symptoms by duodenal lipid during gastric distension.
authors.affiliation: Gastroenterology Division, University Hospital Zürich, Switzerland. christine.feinle@adelaide.edu.au
authors.forename: C
authors.initials: C
authors.lastname: Feinle
authors.forename: O
authors.initials: O
authors.lastname: Meier
authors.forename: B
authors.initials: B
authors.lastname: Otto
authors.forename: M
authors.initials: M
authors.lastname: D'Amato
authors.forename: M
authors.initials: M
authors.lastname: Fried
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D016022:Case-Control Studies; D002766:Cholecystokinin / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004386:Duodenum / Q000378:metabolism; D004415:Dyspepsia / Q000097:blood / Q000209:etiology*; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D006801:Humans; D008055:Lipids / Q000008:administration & dosage / Q000502:physiology*; D008297:Male; D008365:Manometry; D008875:Middle Aged; D010421:Pentanoic Acids / Q000494:pharmacology*; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*
chemical_list: D005765:Gastrointestinal Agents; D008055:Lipids; D010421:Pentanoic Acids; D011949:Receptors, Cholecystokinin; C103490:dexloxiglumide; D002766:Cholecystokinin